SCHEMBL4719446

SCHEMBL4719446

N#Cc1cc(F)c(F)c(N2CCC3(CC2)CCN([C@H]2CC[C@@H](O)CC2)C3=O)c1

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.35
HSD11B1 P28845 7/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
PDE4A P27815 1/20 0.32
HRH3 Q9Y5N1 3/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
AOC3 Q16853 1/20 0.30
BACE1 P56817 1/20 0.30
SCN9A Q15858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5631276 1.00 FFAR4 (0.35) FFAR4HSD11B1HCRTR1HCRTR2PDE4A
SCHEMBL4721479 0.88 HSD11B1 (0.36) HSD11B1HCRTR1HCRTR2PDE4AHRH3
SCHEMBL4722997 0.88 HSD11B1 (0.36) HSD11B1HCRTR1HCRTR2PDE4AHRH3
SCHEMBL4824424 0.88 HSD11B1 (0.36) HSD11B1HCRTR1HCRTR2PDE4AHRH3
SCHEMBL5631278 0.87 HCRTR1 (0.40) FFAR4HSD11B1HCRTR1HCRTR2PDE4A
SCHEMBL4829848 0.87 ALDH1A1 (0.40) FFAR4HSD11B1HCRTR1HCRTR2HRH3
SCHEMBL4718438 0.87 ALDH1A1 (0.40) FFAR4HSD11B1HCRTR1HCRTR2HRH3
SCHEMBL4722964 0.87 ALDH1A1 (0.40) FFAR4HSD11B1HCRTR1HCRTR2HRH3
SCHEMBL4723808 0.87 HCRTR1 (0.40) FFAR4HSD11B1HCRTR1HCRTR2PDE4A
SCHEMBL10112744 0.80 FFAR4 (0.35) FFAR4HSD11B1HRH3SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US claimed
EP-1957494-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-08-20 EP claimed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO claimed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US claimed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
EP-1957494-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-08-20 EP disclosed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO disclosed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129345-A1 Lactam compounds and methods of using the same HSD11B1, HSD17B11, HSD17B1 FFAR4 4151/4885HSD11B1 1/4885HCRTR1 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.